Diabetic Macular Edema (DME) Clinical Trials

Find Diabetic Macular Edema (DME) Clinical Trials Near You

Prospective Evaluation of Blepharoptosis Development in Patients Undergoing Repeated Intravitreal Anti-VEGF Injections

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Intravitreal anti-VEGF injections are a mainstay of treatment for retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion, and usually require repeated administration over years. During each injection an eyelid speculum holds the lids open and the upper eyelid is exposed to repeated mechanical stretch. Aponeurotic ptosis after intraocular surgery is well described, but evidence on blepharoptosis after repeated intravitreal injections is limited and conflicting. This single-center prospective observational study enrolls 60 patients who are starting intravitreal anti-VEGF therapy in one eye only; the untreated fellow eye of each patient serves as an internal control. Upper eyelid position and function are assessed with margin reflex distance-1 (MRD-1), margin reflex distance-2 (MRD-2) and levator function at baseline and at months 1, 3 and 6. The primary endpoint is the difference between the injected eye and the fellow eye in the change in MRD-1 from baseline to month 6.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18 years or older

• Planned initiation of intravitreal anti-VEGF injection in one eye only for a retinal disease

• No prior intravitreal injection in either eye

• Able to attend the scheduled follow-up visits and to cooperate for the duration of the study

• Reliable MRD-1, MRD-2 and levator function measurement possible in both eyes (clear corneal light reflex, clearly visible eyelid margin, able to maintain primary gaze)

• Signed informed consent

Locations
Other Locations
Turkey
University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital
RECRUITING
Istanbul
Contact Information
Primary
Abdulkadir Küçük, MD
akkucuk42@gmail.com
+90 538 572 5722
Backup
Fatih Çoban, MD
cobanfatih_92@hotmail.com
+90 5392346206
Time Frame
Start Date: 2026-09-25
Estimated Completion Date: 2027-07-05
Participants
Target number of participants: 60
Treatments
Patients starting unilateral intravitreal anti-VEGF therapy
Adults with a retinal disease starting intravitreal anti-VEGF injections in one eye only. In each participant the injected eye is the study eye and the non-injected fellow eye is the internal control. Both eyes are assessed for MRD-1, MRD-2 and levator function at baseline and at months 1, 3 and 6.
Sponsors
Leads: Abdulkadir Küçük

This content was sourced from clinicaltrials.gov